G. Mani Subramanian

25.5k total citations · 6 hit papers
141 papers, 8.5k citations indexed

About

G. Mani Subramanian is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, G. Mani Subramanian has authored 141 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Hepatology, 101 papers in Epidemiology and 21 papers in Infectious Diseases. Recurrent topics in G. Mani Subramanian's work include Hepatitis C virus research (75 papers), Liver Disease Diagnosis and Treatment (72 papers) and Hepatitis B Virus Studies (53 papers). G. Mani Subramanian is often cited by papers focused on Hepatitis C virus research (75 papers), Liver Disease Diagnosis and Treatment (72 papers) and Hepatitis B Virus Studies (53 papers). G. Mani Subramanian collaborates with scholars based in United States, Canada and France. G. Mani Subramanian's co-authors include John G. McHutchison, Edward Gane, John F. Flaherty, Nezam H. Afdhal, Anuj Gaggar, Patrick Marcellin, Raul Aguilar Schall, Marı́a Buti, Robert P. Myers and Kathryn M. Kitrinos and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

G. Mani Subramanian

135 papers receiving 8.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

2012 1.3k citations Patrick Marcellin, Edward Gane et al. profile →
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

2014 592 citations Robert Flisiak, Evguenia S. Svarovskaia et al. profile →
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

2017 435 citations Eric Lawitz, Stephen H. Caldwell et al. Hepatology profile →
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

2018 257 citations Eric Lawitz, Lulu Wang et al. profile →
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

2019 255 citations Stephen H. Caldwell, Mitchell L. Shiffman et al. Hepatology profile →
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Mani Subramanian United States	47	6.5k	5.8k	1.3k	1.0k	648	141	8.5k
Hans L. Tillmann Germany	53	6.4k 1.0×	6.3k 1.1×	1.0k 0.8×	838 0.8×	588 0.9×	234	8.9k
Keyur Patel United States	47	5.2k 0.8×	5.3k 0.9×	1.8k 1.4×	416 0.4×	509 0.8×	175	8.5k
Marc G. Ghany United States	58	12.4k 1.9×	12.0k 2.1×	1.1k 0.9×	1.5k 1.4×	975 1.5×	188	15.1k
Chau‐Ting Yeh Taiwan	45	4.4k 0.7×	4.1k 0.7×	2.2k 1.7×	648 0.6×	721 1.1×	292	8.0k
Fumitaka Suzuki Japan	54	9.1k 1.4×	9.6k 1.7×	778 0.6×	1.1k 1.1×	424 0.7×	404	11.5k
M. Diago Spain	34	10.8k 1.7×	10.7k 1.8×	683 0.5×	990 1.0×	497 0.8×	131	12.8k
Jing‐hsiung James Ou United States	44	4.3k 0.7×	2.6k 0.5×	2.9k 2.3×	663 0.7×	834 1.3×	100	7.6k
Theo Heller United States	46	4.0k 0.6×	3.3k 0.6×	1.2k 0.9×	605 0.6×	1.5k 2.3×	235	7.3k
Pietro Lampertico Italy	54	12.0k 1.9×	11.1k 1.9×	994 0.8×	1.2k 1.2×	1.3k 1.9×	418	14.5k
T. Jake Liang United States	68	9.1k 1.4×	8.9k 1.5×	2.3k 1.8×	1.6k 1.6×	1.7k 2.7×	195	13.2k

Countries citing papers authored by G. Mani Subramanian

Since Specialization

Citations

This map shows the geographic impact of G. Mani Subramanian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Mani Subramanian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Mani Subramanian more than expected).

Fields of papers citing papers by G. Mani Subramanian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Mani Subramanian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Mani Subramanian. The network helps show where G. Mani Subramanian may publish in the future.

Co-authorship network of co-authors of G. Mani Subramanian

This figure shows the co-authorship network connecting the top 25 collaborators of G. Mani Subramanian. A scholar is included among the top collaborators of G. Mani Subramanian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Mani Subramanian. G. Mani Subramanian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Subramanian, G. Mani, Adam Hage, Friederike Feldmann, et al.. (2024). AP3B1 Has Type I Interferon-Independent Antiviral Function against SARS-CoV-2. Viruses. 16(9). 1377–1377.

Gane, Edward, Ryan S. Huss, Eisuke Murakami, et al.. (2023). Abstract 12564: Safety, Pharmacokinetics, and Lipid Lowering Effects of the Oral, Liver-Targeted Liver X Receptor (LXR) Inverse Agonist TLC-2716 in Healthy Volunteers. Circulation. 148(Suppl_1). 2 indexed citations

Lawitz, Eric, Kelvin W. Li, Edna Nyangau, et al.. (2022). Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. Journal of Lipid Research. 63(9). 100250–100250. 19 indexed citations

Ponia, Sanket S., Shelly J. Robertson, Kristin L. McNally, et al.. (2021). Mitophagy antagonism by ZIKV reveals Ajuba as a regulator of PINK1 signaling, PKR-dependent inflammation, and viral invasion of tissues. Cell Reports. 37(4). 109888–109888. 30 indexed citations

Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, et al.. (2019). The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.. Hepatology. 3 indexed citations

Chaturvedi, Nimisha, Evguenia S. Svarovskaia, Hongmei Mo, et al.. (2019). Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. eLife. 8. 11 indexed citations

Trauner, Michael, Yevgeniy Gindin, Zhaoshi Jiang, et al.. (2019). Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. JHEP Reports. 2(1). 100060–100060. 14 indexed citations

Agarwal, Kosh, Sang Hoon Ahn, Audrey Lau, et al.. (2018). Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. Journal of Viral Hepatitis. 25(11). 1331–1340. 71 indexed citations

Subramanian, G. Mani, Teodora Kuzmanovic, Ying Zhang, et al.. (2018). A new mechanism of interferon’s antiviral action: Induction of autophagy, essential for paramyxovirus replication, is inhibited by the interferon stimulated gene, TDRD7. PLoS Pathogens. 14(1). e1006877–e1006877. 50 indexed citations

10.

Lim, Seng Gee, Rosmawati Mohamed, Phuong Le, et al.. (2018). IDDF2018-ABS-0112 Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1–6 hcv infected population from singapore, malaysia, thailand, and vietnam: results from a phase 3, clinical trial. A100.1–A100. 2 indexed citations

11.

Chan, Henry Lik‐Yuen, Marı́a Buti, Robert Flisiak, et al.. (2018). IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). A97.1–A97. 2 indexed citations

12.

Brunetto, Maurizia Rossana, Aric J. Hui, Rajiv Mehta, et al.. (2018). IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB). A97.2–A98. 1 indexed citations

13.

Bayliss, Julianne, Lilly Yuen, Gillian Rosenberg, et al.. (2016). Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 66(11). 2013–2023. 38 indexed citations

14.

Talal, Andrew H., et al.. (2013). 1319 SIMTUZUMAB, AN ANTIFIBROTIC MONOCLONAL ANTIBODY AGAINST LYSYL OXIDASE-LIKE 2 (LOXL2) ENZYME, APPEARS SAFE AND WELL TOLERATED IN PATIENTS WITH LIVER DISEASE OF DIVERSE ETIOLOGY. Journal of Hepatology. 58. S532–S532. 17 indexed citations

15.

Neumann, Avidan U., et al.. (2008). 818 VIRAL KINETICS AND PHARMACODYNAMICS OF ALBINTERFERON ALFA-2B IN INTERFERON TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C. Journal of Hepatology. 48. S306–S306. 1 indexed citations

16.

Balan, Vijayan, David R. Nelson, Mark Sulkowski, et al.. (2006). Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.. PubMed. 11(7). 901–8. 12 indexed citations

17.

Cui, Xizhong, Yan Li, Mahtab Moayeri, et al.. (2005). Late Treatment with a Protective Antigen–Directed Monoclonal Antibody Improves Hemodynamic Function and Survival in a Lethal Toxin–Infused Rat Model of Anthrax Sepsis. The Journal of Infectious Diseases. 191(3). 422–434. 56 indexed citations

18.

Subramanian, G. Mani, et al.. (2005). A Phase 1 Study of PAmAb, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clinical Infectious Diseases. 41(1). 12–20. 75 indexed citations

19.

Subramanian, G. Mani, et al.. (2003). Gliclazide‐induced hepatitis. Practical Diabetes International. 20(1). 18–20. 4 indexed citations

20.

Subramanian, G. Mani, et al.. (1994). A more general comparison of the decision table and tree. Communications of the ACM. 37(2). 109–113. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact